JAMA Editors' Summary: On research in medicine, science, & clinical practice. For physicians, researchers, & clinicians.

Treatment of agitation in Alzheimer disease, text messaging for CV risk modification, a newly approved PCSK9 inhibitor for dyslipidemia, and more.

September 22, 20158 min

Chat About Treatment of agitation in Alzheimer disease, text messaging for CV risk modification, a newly approved PCSK9 inhibitor for dyslipidemia, and more.

For You